Biogen Lowers Full-Year Profit Forecast

Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

More In Business

Big Business This Week: Does the Dollar’s decline matter?

A quiet downturn has been underway since the beginning of the most recent Administration, as the U.S. dollar weakens. But does it matter?

Inside Drew Brees’ Secret Weapon for Flexibility, Performance, and Longevity

Drew Brees and Tony Zaccario join us at the NYSE to discuss how Stretch Zone is transforming recovery, flexibility, and performance nationwide.

Five-Star Frenzy: The Hotels Redefining Luxury in 2026

Luxury travel is surging, with 2026 bookings up 30–40%. Forbes Travel Guide reveals new hotspots, five-star trends, and what’s driving the $181B boom.

The Floral Brand Disrupting Valentine’s Day Delivery

With $3B spent on Valentine’s flowers, UrbanStems CEO Meenakshi Lala shares trends, tech innovations, and how gifting is evolving for 2026.

The Real Estate Bets Paying Off in 2026 Aren’t the Obvious Ones

Rich Hill of Principal Asset Management breaks down where real estate capital is flowing, what’s driving returns, and how 2026 could reshape the market.

One Trend Quietly Dominated Super Bowl 60 Ads, and It’s a Game Changer

From surprise celebrity overload to fewer influencers, USA Today's Ralphie Aversa breaks down the biggest Super Bowl 60 ads and why AI quietly stole the show.

Load More